New Study Demonstrates that Running Does Not Increase Risk of Arthritis

Chicago Marathon®participants helped orthopaedic researchers further understand the impact of long-distance running on bone and joint health, specifically knee and hip arthritis in recreational runners. Results from the largest survey of marathon runners ever conducted showed no association between cumulative running history and the risk for arthritis.

“Despite growing knowledge that running and being active can be healthy for your joints, there is a continued dogma among the healthcare community that patients should stop running to avoid wearing out their cartilage,” said lead author Matthew J. Hartwell, MD, an orthopaedic surgery sports medicine fellow at University of California San Francisco. “In fact, our survey showed that one in four people have received a recommendation by their physician to reduce their running volume, and for those with arthritis, nearly 50% of runners were told by their physicians to stop running altogether.”

Dr. Hartwell and his colleagues conducted the prospective cohort study, “Does Running Increase the Risk for Hip and Knee Arthritis? A Survey of 3,804 Chicago Marathon Runners,” during his residency at Northwestern University Feinberg School of Medicine in Chicago. It was presented at the 2023 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS).

The electronic survey was completed by 3,804 participants registered for the 2019 and 2021 Chicago Marathons. The mean age of respondents was 43.9. Participants had run an average of five or fewer marathons, and they had been running for an average of 14.7 years.

The survey featured 30 questions targeted at assessing:

  • Demographic information (age, sex, height, weight, country of origin and occupation)
  • Running history (number of years running; average weekly mileage over the past year; average running pace during training runs; number of marathons completed, including ultra-marathons; and participation with cross training)
  • Hip/knee health (occurrence of hip or knee pain over the past year that prevented running; a history of hip or knee injuries that required a break in running; a family history of hip and/or knee arthritis; surgical procedures performed on the hip or knee; and receiving a hip or knee arthritis diagnosis)

These data showed that the prevalence of hip and/or knee arthritis was 7.3%. Prior hip/knee injuries or surgery, advancing age, family history and BMI were risk factors for arthritis. Cumulative number of years running, number of marathons completed, weekly mileage and mean running pace proved not to be significant risk factors for arthritis.

“Our multivariate analysis showed that the factors that increase a person’s risk for arthritis are the same for anyone with joint degeneration — whether or not they’re a runner. Those factors include increase in age, BMI, a family history of hip or knee arthritis, and whether they’ve had injuries or knee surgery,” said Dr. Hartwell.

The participants were also asked if a doctor had ever advised them to stop or reduce their running, if they were still running at the time of questionnaire completion, and if they plan to run another marathon. The majority (94.2%) of runners planned to run another marathon despite 24.2% of all participants being told by a physician to do otherwise.

“Recreational runners are a dedicated group of people who use the sport for exercise, mental clarity or to challenge themselves,” said Vehniah K. Tjong, MD, FAAOS, associate professor of orthopaedic surgery at Northwestern University. “Our hope is these findings educate physicians, so they don’t instinctively advise against running and they work to meet patients on their level — because, as these data show, runners are likely to continue running despite medical advice.”

2023 AAOS Annual Meeting Disclosure Statement

SourceAAOS

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version